SARS‐CoV‐2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest

Abstract

SummaryBackgroundLimited data exist on the characteristics of SARS‐CoV‐2 infections in German patients with psoriasis or psoriasis arthritis (PsA). This study analyses COVID‐19 prevalence and severity of symptoms in these patients.Patients and MethodsParticipants of the German registries PsoBest and CoronaBest were surveyed in February 2022. Descriptive analyses were conducted.Results4,818 patients were included in the analysis, mean age of 56.4 years. Positive SARS‐CoV‐2 tests were reported by 737 (15.3%) patients. The most frequently reported acute symptoms were fatigue (67.3%), cough (58.8%), and headache (58.3%). Longer‐lasting symptoms after COVID‐19 were reported by 231 of 737 patients after the acute phase. For most patients (92.9%), systemic treatment for their psoriasis or PsA was not modified during the pandemic. Patients positively tested for SARS‐CoV‐2 were younger on average and had more often changes in the therapy of psoriasis than negatively tested patients (8.5% vs. 5.4%).ConclusionsIn this cohort of patients with psoriasis or PsA undergoing systemic treatment, SARS‐CoV‐2 infections were common but less frequent than in the general German population. No risk signals for more severe COVID‐19 or increased infection rates were observed in the patients. In addition, systemic treatments remained largely unchanged, so that no risks can be attributed to these therapies.